MoonLake Immunotherapeutics
MLTX
$55.65
$0.811.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.56M | 34.54M | 30.32M | 28.03M | 26.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 200.88M | 170.76M | 143.09M | 108.54M | 78.40M |
| Operating Income | -200.88M | -170.76M | -143.09M | -108.54M | -78.40M |
| Income Before Tax | -178.74M | -147.46M | -120.96M | -82.45M | -58.02M |
| Income Tax Expenses | 381.20K | 365.20K | 282.20K | 285.40K | 222.20K |
| Earnings from Continuing Operations | -179.12 | -147.83 | -121.24 | -82.74 | -58.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 2.96M | 2.62M | 2.31M | 1.97M | 3.44M |
| Net Income | -176.16M | -145.21M | -118.93M | -80.77M | -54.80M |
| EBIT | -200.88M | -170.76M | -143.09M | -108.54M | -78.40M |
| EBITDA | -198.42M | -168.70M | -141.09M | -107.48M | -77.37M |
| EPS Basic | -2.79 | -2.30 | -1.89 | -1.29 | -0.90 |
| Normalized Basic EPS | -1.72 | -1.42 | -1.16 | -0.79 | -0.54 |
| EPS Diluted | -2.79 | -2.30 | -1.89 | -1.29 | -0.90 |
| Normalized Diluted EPS | -1.72 | -1.42 | -1.16 | -0.79 | -0.54 |
| Average Basic Shares Outstanding | 252.48M | 252.08M | 251.48M | 248.32M | 238.94M |
| Average Diluted Shares Outstanding | 252.48M | 252.08M | 251.48M | 248.32M | 238.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |